Last reviewed 2026-05-13 · How we verify

Vanicream- Dupilumab-naïve

National Institute of Allergy and Infectious Diseases (NIAID) · FDA-approved active Small molecule

Vanicream- Dupilumab-naïve is a Small molecule drug developed by National Institute of Allergy and Infectious Diseases (NIAID). It is currently FDA-approved for Dry skin, eczema-prone skin, and sensitive skin care.

Vanicream is a fragrance-free, dye-free moisturizing cream that provides skin barrier support without common irritants.

Vanicream is a fragrance-free, dye-free moisturizing cream that provides skin barrier support without common irritants. Used for Dry skin, eczema-prone skin, and sensitive skin care.

At a glance

Generic name	Vanicream- Dupilumab-naïve
Sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Modality	Small molecule
Therapeutic area	Dermatology
Phase	FDA-approved

Mechanism of action

Vanicream is a topical emollient formulation designed to hydrate and protect the skin barrier by occluding moisture and reducing transepidermal water loss. It is free of common sensitizing ingredients such as dyes, fragrance, lanolin, parabens, and formaldehyde releasers, making it suitable for sensitive or compromised skin. The product is not a drug with a molecular mechanism of action but rather a cosmetic/skincare product.

Approved indications

Dry skin, eczema-prone skin, and sensitive skin care

Common side effects

No common side effects on file.

Key clinical trials

Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Vanicream- Dupilumab-naïve CI brief — competitive landscape report
Vanicream- Dupilumab-naïve updates RSS · CI watch RSS
National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI

Frequently asked questions about Vanicream- Dupilumab-naïve

What is Vanicream- Dupilumab-naïve?

Vanicream- Dupilumab-naïve is a Small molecule drug developed by National Institute of Allergy and Infectious Diseases (NIAID), indicated for Dry skin, eczema-prone skin, and sensitive skin care.

How does Vanicream- Dupilumab-naïve work?

Vanicream is a fragrance-free, dye-free moisturizing cream that provides skin barrier support without common irritants.

What is Vanicream- Dupilumab-naïve used for?

Vanicream- Dupilumab-naïve is indicated for Dry skin, eczema-prone skin, and sensitive skin care.

Who makes Vanicream- Dupilumab-naïve?

Vanicream- Dupilumab-naïve is developed and marketed by National Institute of Allergy and Infectious Diseases (NIAID) (see full National Institute of Allergy and Infectious Diseases (NIAID) pipeline at /company/national-institute-of-allergy-and-infectious-diseases-niaid).

What development phase is Vanicream- Dupilumab-naïve in?

Vanicream- Dupilumab-naïve is FDA-approved (marketed).

Manufacturer: National Institute of Allergy and Infectious Diseases (NIAID) — full pipeline
Therapeutic area: All drugs in Dermatology
Indication: Drugs for Dry skin, eczema-prone skin, and sensitive skin care
Compare: Vanicream- Dupilumab-naïve vs similar drugs
Pricing: Vanicream- Dupilumab-naïve cost, discount & access